DE202012003949U1 - Choline, L (+) - lactic acid and B vitamins containing composition - Google Patents
Choline, L (+) - lactic acid and B vitamins containing composition Download PDFInfo
- Publication number
- DE202012003949U1 DE202012003949U1 DE202012003949U DE202012003949U DE202012003949U1 DE 202012003949 U1 DE202012003949 U1 DE 202012003949U1 DE 202012003949 U DE202012003949 U DE 202012003949U DE 202012003949 U DE202012003949 U DE 202012003949U DE 202012003949 U1 DE202012003949 U1 DE 202012003949U1
- Authority
- DE
- Germany
- Prior art keywords
- range
- choline
- vitamin
- lactic acid
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 title claims abstract description 34
- 229960001231 choline Drugs 0.000 title claims abstract description 26
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 235000019156 vitamin B Nutrition 0.000 title claims description 7
- 239000011720 vitamin B Substances 0.000 title claims description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Natural products N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 11
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 8
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 7
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 7
- 229960002685 biotin Drugs 0.000 claims description 7
- 235000020958 biotin Nutrition 0.000 claims description 7
- 239000011616 biotin Substances 0.000 claims description 7
- 229960002477 riboflavin Drugs 0.000 claims description 7
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 229930003451 Vitamin B1 Natural products 0.000 claims description 6
- 229930003779 Vitamin B12 Natural products 0.000 claims description 6
- 229930003471 Vitamin B2 Natural products 0.000 claims description 6
- 235000019152 folic acid Nutrition 0.000 claims description 6
- 239000011724 folic acid Substances 0.000 claims description 6
- 239000011713 pantothenic acid Substances 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- 229960003495 thiamine Drugs 0.000 claims description 6
- 235000010374 vitamin B1 Nutrition 0.000 claims description 6
- 239000011691 vitamin B1 Substances 0.000 claims description 6
- 235000019163 vitamin B12 Nutrition 0.000 claims description 6
- 239000011715 vitamin B12 Substances 0.000 claims description 6
- 235000019164 vitamin B2 Nutrition 0.000 claims description 6
- 239000011716 vitamin B2 Substances 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 4
- 239000004383 Steviol glycoside Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 235000014666 liquid concentrate Nutrition 0.000 claims description 4
- 229940055726 pantothenic acid Drugs 0.000 claims description 4
- 235000019161 pantothenic acid Nutrition 0.000 claims description 4
- 229930182488 steviol glycoside Natural products 0.000 claims description 4
- 235000019411 steviol glycoside Nutrition 0.000 claims description 4
- 150000008144 steviol glycosides Chemical class 0.000 claims description 4
- 235000019202 steviosides Nutrition 0.000 claims description 4
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 4
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- RPERJPYDELTDMR-UHFFFAOYSA-K 2-hydroxyethyl(trimethyl)azanium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound C[N+](C)(C)CCO.C[N+](C)(C)CCO.C[N+](C)(C)CCO.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O RPERJPYDELTDMR-UHFFFAOYSA-K 0.000 claims 1
- 229960003257 choline citrate Drugs 0.000 claims 1
- 238000000855 fermentation Methods 0.000 claims 1
- 230000004151 fermentation Effects 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 229940046001 vitamin b complex Drugs 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 239000004310 lactic acid Substances 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 4
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 208000004481 Choline Deficiency Diseases 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000021752 choline deficiency disease Diseases 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000010224 hepatic metabolism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000001161 sympathoadrenergic effect Effects 0.000 description 2
- 235000008979 vitamin B4 Nutrition 0.000 description 2
- 239000011579 vitamin B4 Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 210000003617 erythrocyte membrane Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029219 regulation of pH Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 235000020806 vegan diet Nutrition 0.000 description 1
- 235000003563 vegetarian diet Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
Eine Cholin und L-(+)-Milchsäure enthaltende Zusammensetzung dadurch gekennzeichnet, dass die Zusammensetzung, bezogen auf eine Tagesdosis der Zusammensetzung, als wirksame Bestandteile umfasst: – L(+)-Milchsäure im Bereich von >= 100 mg bis <= 6000 mg, vorzugsweise im Bereich von >= 1000 mg bis <= 4000 mg, bevorzugt im Bereich von >= 2500 mg bis <= 3400 mg; und/oder – Cholin im Bereich von >= 20 mg bis <= 2000 mg, vorzugsweise im Bereich von >= 100 mg bis <= 1000 mg, bevorzugt im Bereich von >= 400 mg bis <= 600 mg.A composition containing choline and L - (+) - lactic acid, characterized in that the composition, based on a daily dose of the composition, comprises as active ingredients: L (+) - lactic acid in the range from> = 100 mg to <= 6000 mg , preferably in the range from 1000 mg to 4000 mg, preferably in the range from 2500 mg to 3400 mg; and / or choline in the range from> 20 mg to 2000 mg, preferably in the range from 100 mg to 1000 mg, preferably in the range from 400 mg to 600 mg.
Description
Die vorliegende Erfindung betrifft eine Cholin, L-(+)-Milchsäure und B-Vitamine enthaltende Zusammensetzung, welche insbesondere als Nahrungsergänzung bei stress- und ernährungsbedingten Mangel an Cholin und B-Vitaminen sowie der Unterstützung des gesunden Leberstoffwechsels, des Energiestoffwechsels, der Funktion von Nervenzellen und Psyche, der neurovegetativen Balance, der Reduktion von Müdigkeit und der Regulation des Darmmilieus dient. Insbesondere ist das Mittel auch geeignet, um einen Cholinmangel während der Schwangerschaft und Stillzeit, bei regelmäßigem Alkoholgenuss oder bei vegetarischer und veganer Ernährung als Nahrungsergänzungsmittel oder ergänzende bilanzierte Diät zu decken.The present invention relates to a composition containing choline, L - (+) - lactic acid and B vitamins, which is particularly useful as a dietary supplement in stress and nutritional deficiencies of choline and B vitamins and in support of healthy liver metabolism, energy metabolism, function of Nerve cells and psyche, the neurovegetative balance, the reduction of fatigue and the regulation of the intestinal environment. In particular, the agent is also suitable to cover a choline deficiency during pregnancy and lactation, with regular consumption of alcohol or in vegetarian and vegan diet as a dietary supplement or supplemental balanced diet.
Im Stand der Technik sind Milchsäureprodukte mit schwankender und meist niedriger Konzentration, B-Vitamine und Cholinhaltige Produkte, insbesondere Lecithin, bekannt. Der wirkungsvolle Synergismus zwischen Milchsäure und Cholin und B-Vitaminen ist bislang nicht beschrieben.In the prior art lactic acid products with fluctuating and usually low concentration, B vitamins and choline-containing products, especially lecithin known. The effective synergism between lactic acid and choline and B vitamins is not yet described.
Cholin ist essentiell für den Homocystein-Abbau und den Abtransport von Fetten und Cholesterin aus der Leber. Cholin wird in der Synthese der Phospholipide und Sphingomyeline der Zellmembranen benötigt und ist insbesondere für die Myelinscheiden der Nervenzellen wichtig. Der Cholingehalt der Membran ist essenziell für die zelluläre Funktion, Schutz und Flexibilität. Cholin ist ein Vorläufer des Neurotransmitters Acetylcholin, der bei der Muskelkontrolle, beim Gedächtnis, im vegetativen Nervensystem und vielen anderen Funktionen eine zentrale Rolle spielt. Cholin spielt eine wichtige Rolle im Neurovegetativum, indem es den komplett durch Acetylcholin gesteuerten Parasympathikus stärkt und damit auch günstige Effekte bei vegetativer Dystonie zeigen kann.Choline is essential for homocysteine breakdown and the removal of fats and cholesterol from the liver. Choline is needed in the synthesis of phospholipids and sphingomyelin of cell membranes and is particularly important for myelin sheaths of nerve cells. The choline content of the membrane is essential for cellular function, protection and flexibility. Choline is a precursor to the neurotransmitter acetylcholine, which plays a central role in muscle control, memory, the autonomic nervous system, and many other functions. Choline plays an important role in the neurovegetative, by strengthening the completely controlled by acetylcholine parasympathetic and thus can also show beneficial effects in vegetative dystonia.
Fett und Cholesterin aus der Nahrung werden mittels Lipoproteinen (Chylomikronen) zur Leber transportiert. In der Leber werden Fett und Cholesterin in VLDL-Lipoproteine mit sehr geringer Dichte verpackt, um sie durchs Blut zu den Geweben zu transportieren. Phosphatidylcholin ist ein notwendiger Bestandteil dieser VLDL-Partikel, ohne den sich Fett und Cholesterin in der Leber ansammeln.Dietary fat and cholesterol are transported to the liver via lipoproteins (chylomicrons). In the liver, fat and cholesterol are packaged in very low density VLDL lipoproteins to transport them through the blood to the tissues. Phosphatidylcholine is a necessary component of these VLDL particles, without which fat and cholesterol accumulate in the liver.
Cholin kann im Körper zu Betain verstoffwechselt werden. Betain ist selbst ein wichtiger Mikronährstoff und eine Quelle von Methyl-Gruppen (Formel: CH3), die für Methylierungsreaktionen benötigt werden. Die Methylierung ist eine besonders wichtige chemische Reaktion in der Phase-2-Entgiftung der Leber. Hierfür werden Methylgruppen-Donatoren wie Cholin benötigt. Cholin, das vom griechischen Wort chole (Galle) abstammt, ist Bestandteil der Gallenflüssigkeit und wichtig für die Prävention von Gallensteinen.Choline can be metabolized in the body to betaine. Betaine itself is an important micronutrient and source of methyl groups (formula: CH3) needed for methylation reactions. Methylation is a particularly important chemical reaction in the phase 2 detoxification of the liver. For this purpose, methyl group donors such as choline are needed. Choline, which is derived from the Greek word chole (bile), is a component of bile and important for the prevention of gallstones.
In der Schwangerschaft und in der Stillzeit ist der Cholin-Bedarf ist erheblich höher, weil Cholin für die Entwicklung des ungeborenen und neugeborenen Kindes eine zentrale Rolle spielt. Cholinmangel erhöht u. a. das Risiko einer spina bifida.Choline needs are significantly higher during pregnancy and breastfeeding because choline plays a central role in developing the unborn and newborn children. Choline deficiency increases u. a. the risk of a spina bifida.
Die rechtsdrehende L(+)-Milchsäure wird in der Volks- und Naturheilkunde hoch geschätzt. Die vielfachen Wirkmechanismen sind letztlich nur zum Teil geklärt. Sicherlich dient die L(+)-Milchsäure der Wiederherstellung eines gesunden, leicht sauren Dickdarmmilieus. In einem sauren Dickdarm wird das gasförmige Ammoniak, das den Energiestoffwechsel in der Leber massiv belastet, als ungiftiges Ammonium-Salz ausgeschieden. Die Leber wird entlastet und kann besser metabolische Säuren abbauen. Zusätzlich wird die Milchsäure von Darmbakterien zum Krebshemmstoff Butyrat abgebaut. Ein alkalischer Dickdarm-pH steigert das Risiko von Dickdarmkrebs, weil die Giftung der Gallensäuren zu kanzerogenen sekundären Gallensäuren gefördert wird. Eine Absenkung des Dickdarm-pHs in den leicht sauren Bereich hat diverse positive Effekte.The dextrorotatory L (+) - lactic acid is highly valued in folk and naturopathy. The multiple mechanisms of action are ultimately only partially clarified. Certainly, L (+) - lactic acid is used to restore a healthy, slightly acidic, large intestinal milieu. In an acidic large intestine, gaseous ammonia, which massively pollutes the energy metabolism in the liver, is excreted as a non-toxic ammonium salt. The liver is relieved and can break down better metabolic acids. In addition, the lactic acid of intestinal bacteria is degraded to the anti-cancerous butyrate. An alkaline colonic pH increases the risk of colon cancer by promoting the toxicity of bile acids to carcinogenic secondary bile acids. Lowering the pH of the colon to the slightly acidic region has various positive effects.
Bei chronischen Erkrankungen und Gewebsazidose ist das venöse Blut meist zu alkalisch, während die Bicarbonat-Pufferreserven reduziert sind. Die tiefere Ursache liegt in einer mitochondrialen Dysfunktion (verminderten Zellatmung), wodurch weniger Kohlendioxid und damit Bicarbonat von den Zellen ins venöse Blut abgegeben wird. Nach Dr. Dr. Paul Gerhardt Seeger steigert die L(+)-Milchsäure die Zellatmung deutlich. Die Milchsäure gelangt in Darm und wird zum Teil auch ins Blut resorbiert. Dort wirkt sie als Signalmolekül und übt einen „Trainingseffekt” auf Erythrozyten und Gewebe aus. Unter regelmäßiger Milchsäure-Belastung (durch die Ernährung oder durch Sport) werden verstärkt Monocarbocylat-Transporter (MCT) in der Erythrozytenmembram exprimiert. Die „trainierten” Erythrozyten können dadurch verstärkt bei Bedarf Milchsäure aus dem Plasma aufnehmen. Dies erhöht den Gradienten zwischen Gewebe bzw. Muskel und Plasma, was wiederum einen erhöhten Protonen-Efflux aus dem Gewebe ermöglicht: Muskel und Gewebe können ihre Säuren ans Plasma verstärkt abgeben und entsäuern. Dieser Effekt bewirkt insgesamt eine verbesserte Protonenaufnahmefähigkeit und Pufferfähigkeit der Erythrozyten. Insbesondere bei Krebserkrankungen kann ein solchermaßen trainiertes System die Tumormilchsäure, welche den Tumor schützt und die Metastasierung vorantreibt, effektiver aus dem Gewebe entfernen und unschädlich machen. Das MCT-Transportsystem hat unter Belastung den größten Stellenwert bei der pH-Regulation, weil es seine Transportleistung deutlich steigern kann. Die MCTs bestimmen damit die reale Pufferkapazität eines Gewebes. Hauptaufgabe der Erythrozyten ist bekanntlich der Transport von Sauerstoff und Kohlendioxid. Das Kohlendioxid diffundiert in den Kapillaren in die Erythrozyten, wird dort mit Wasser zu Kohlensäure umgesetzt und reagiert schließlich zu Hydrogencarbonationen und Protonen. L(+)-Milchsäure wirkt gefäßerweiternd und kann in den Erythrozyten die Leistung der Natrium-Kalium-Pumpen sowie das Membranpotential erhöhen. Dadurch wirkt sie der Geldrollenbildung (sludge) entgegen, welche die rheologischen Eigenschaften des Blutes verschlechtert und die Sauerstoffversorgung des Gewebes hemmt.In chronic diseases and tissue acidosis, the venous blood is usually too alkaline, while the bicarbonate buffer reserves are reduced. The underlying cause is mitochondrial dysfunction (diminished cellular respiration), which releases less carbon dioxide and thus bicarbonate from the cells into the venous blood. After Dr. Dr. Paul Gerhardt Seeger significantly increases L (+) - lactic acid cell respiration. The lactic acid gets into the intestine and is partially absorbed into the blood. There it acts as a signal molecule and exerts a "training effect" on erythrocytes and tissue. With regular lactic acid exposure (through diet or exercise), monocarbocylate transporters (MCTs) are increasingly expressed in the erythrocyte membrane. As a result, the "trained" erythrocytes can increasingly absorb lactic acid from the plasma as required. This increases the gradient between tissue or muscle and plasma, which in turn allows an increased proton efflux from the tissue: muscle and tissue can release their acids to the plasma reinforced and deacidified. This effect results in an overall improved proton receptivity and buffering capacity of the erythrocytes. Especially in the case of cancers, such a trained system can be the tumor lactic acid which protects the tumor and the metastasis pushes forward, more effectively remove from the tissue and render harmless. The MCT transport system has the highest priority in pH regulation under load because it can significantly increase its transport performance. The MCTs thus determine the real buffer capacity of a tissue. The main task of the erythrocytes is known to be the transport of oxygen and carbon dioxide. The carbon dioxide diffuses in the capillaries in the erythrocytes, where it is converted into carbonic acid with water and finally reacts to hydrogen carbonate ions and protons. L (+) - lactic acid has a vasodilating effect and can increase the performance of the sodium-potassium pumps and the membrane potential in the erythrocytes. Thus, it counteracts the formation of the roll of paper (sludge), which deteriorates the rheological properties of the blood and inhibits the oxygenation of the tissue.
Laktat ist ein wichtiger Energielieferant: Unter Belastung deckt der Herzmuskel und Nervenzellen vorzugsweise über Laktat seinen Energiebedarf. Laktat wirkt als Pseudo-Hormon auch regulierend auf das sympathikoadrenerge System und gleicht ideal die Cholin-Wirkung aus. Während Milchsäure das sympathikoadrenerge System stärkt, liefert Cholin als Acetylcholin-Baustein den entscheidenden Mikronährstoff für das parasympatikotone System.Lactate is an important source of energy. Under exercise, the heart muscle and nerve cells preferably cover their energy requirements via lactate. Lactate acts as a pseudo-hormone also regulating the sympatho-adrenergic system and ideally compensates for the choline effect. While lactic acid strengthens the sympatho-adrenergic system, choline as the acetylcholine component provides the crucial micronutrient for the parasympatheticotonic system.
Viele dieser positiven Milchsäure-Effekte werden durch sportliche Betätigung erreicht. Die orale Milchsäure-Supplementation ist eine Alternative für Menschen sein, die sich nicht mehr sportlich ausreichend betätigen können, da sie dem Organismus ein physisches Training simuliert. Oral aufgenommene L(+)-Milchsäure wirkt zusätzlich günstig auf den Säure-Basen-Haushalt, indem sie das Darmmilieu reguliert, so die Ammoniak-Entgiftung verbessert und die Leber entlastet.Many of these positive lactic acid effects are achieved through exercise. Oral lactic acid supplementation is an alternative for people who can no longer exercise adequately because they simulate physical training for the organism. Ingested L (+) - lactic acid also has a beneficial effect on the acid-base balance by regulating the intestinal environment, improving ammonia detoxification and relieving the liver.
Überraschend konnte festgestellt werden, dass die erfindungsgemässe Zusammensetzung mit L(+)-Milchsäure, Cholin und den Coenzymen der B-Vitamine sich optimal synergistisch in der Stützung des Leberstoffwechsels verhält, indem das Dickdarmmilieu leicht angesäuert wird und so physiologisch reguliert wird, dadurch der Harnstoffzyklus durch die gesteigerte Ammoniakausscheidung über den Stuhl entlastet wird und die Leber zusätzlich durch den verbesserten Abtransport von Fettsäuren- und Cholesterin entlastet wird. Zusätzlich werden die normale Funktion von Psyche und Nerven sowie der Zellstoffwechsel gefördert. Die Zusammensetzung wirkt ausgleichend auf das Vegetativum, indem sie gleichermaßen beide Seiten des vegetativen Nervensystems stärkt und damit seine Regulationsfähigkeit erhöht.Surprisingly, it could be stated that the composition according to the invention with L (+) - lactic acid, choline and the coenzymes of the B vitamins behaves optimally synergistically in the support of liver metabolism, in that the colonic environment is slightly acidified and thus physiologically regulated, thereby the urea cycle is relieved by the increased ammonia excretion via the stool and the liver is additionally relieved by the improved removal of fatty acids and cholesterol. In addition, the normal function of psyche and nerves as well as cell metabolism are promoted. The composition has a balancing effect on the vegetative system by equally strengthening both sides of the vegetative nervous system and thus increasing its regulatory capacity.
In bevorzugten Ausführungsformen umfasst die Zusammensetzung, bezogen auf eine Tagesdosis der Zusammensetzung, als wirksame Bestandteile die Stoffe:
- – L(+)-Milchsäure im Bereich von >= 100 mg bis <= 6000 mg, vorzugsweise im Bereich von >= 1000 mg bis <= 4000 mg, bevorzugt im Bereich von >= 2500 mg bis <= 3400 mg; und/oder
- – Cholin im Bereich von >= 20 mg bis <= 2000 mg, vorzugsweise im Bereich von >= 100 mg bis <= 1000 mg, bevorzugt im Bereich von >= 400 mg bis <= 600 mg; und/oder
- – Vitamin B1 im Bereich von >= 0,2 mg bis <= 20 mg, vorzugsweise im Bereich von >= 0,5 mg bis <= 10 mg, bevorzugt im Bereich von >= 1,5 mg bis <= 3,2 mg; und/oder
- – Vitamin B2 im Bereich von >= 0,2 mg bis <= 20 mg, vorzugsweise im Bereich von >= 0,5 mg bis <= 10 mg, bevorzugt im Bereich von >= 18 mg bis <= 38 mg; und/oder
- – Niacin im Bereich von >= 3 mg bis <= 60 mg, vorzugsweise im Bereich von >= 10 mg bis <= 30 mg, bevorzugt im Bereich von >= 12 mg bis <= 20 mg; und/oder
- – Vitamin B6 im Bereich von >= 0,2 mg bis <= 20 mg, vorzugsweise im Bereich von >= 0,5 mg bis <= 10 mg, bevorzugt im Bereich von >= 0,9 mg bis <= 3 mg; und/oder
- – Vitamin B12 im Bereich von >= 0,5 μg bis <= 1000 μg, vorzugsweise im Bereich von >= 1 μg bis <= 50 μg, bevorzugt im Bereich von >= 2 μg bis <= 5 μg; und/oder
- – Folsäure im Bereich von >= 50 μg bis <= 1 mg, vorzugsweise im Bereich von >= 100 μg bis <= 500 μg, bevorzugt im Bereich von >= 150 μg bis <= 300 μg; und/oder
- – Pantothensäure im Bereich von >= 2 mg bis <= 100 mg, vorzugsweise im Bereich von >= 4 mg bis <= 40 mg, bevorzugt im Bereich von >= 5 mg bis <= 10 mg; und/oder
- – Biotin im Bereich von >= 20 μg bis <= 800 μg, vorzugsweise im Bereich von >= 30 μg bis <= 200 μg, bevorzugt im Bereich von >= 40 μg bis <= 80 μg; und/oder
- – Steviolglykoside im Bereich von >= 10 mg bis <= 400 mg, vorzugsweise im Bereich von >= 30 mg bis <= 300 mg, bevorzugt im Bereich von >= 80 mg bis <= 200 mg.
- L (+) - lactic acid in the range of> = 100 mg to <= 6000 mg, preferably in the range of> = 1000 mg to <= 4000 mg, preferably in the range of> = 2500 mg to <= 3400 mg; and or
- Choline in the range of> = 20 mg to <= 2000 mg, preferably in the range of> = 100 mg to <= 1000 mg, preferably in the range of> = 400 mg to <= 600 mg; and or
- - Vitamin B1 in the range of> = 0.2 mg to <= 20 mg, preferably in the range of> = 0.5 mg to <= 10 mg, preferably in the range of> = 1.5 mg to <= 3.2 mg; and or
- Vitamin B2 in the range of> = 0.2 mg to <= 20 mg, preferably in the range of> = 0.5 mg to <= 10 mg, preferably in the range of> = 18 mg to <= 38 mg; and or
- Niacin in the range of> = 3 mg to <= 60 mg, preferably in the range of> = 10 mg to <= 30 mg, preferably in the range of> = 12 mg to <= 20 mg; and or
- Vitamin B6 in the range of> = 0.2 mg to <= 20 mg, preferably in the range of> = 0.5 mg to <= 10 mg, preferably in the range of> = 0.9 mg to <= 3 mg; and or
- - Vitamin B12 in the range of> = 0.5 μg to <= 1000 μg, preferably in the range of> = 1 μg to <= 50 μg, preferably in the range of> = 2 μg to <= 5 μg; and or
- Folic acid in the range of> = 50 μg to <= 1 mg, preferably in the range of> = 100 μg to <= 500 μg, preferably in the range of> = 150 μg to <= 300 μg; and or
- Pantothenic acid in the range of> = 2 mg to <= 100 mg, preferably in the range of> = 4 mg to <= 40 mg, preferably in the range of> = 5 mg to <= 10 mg; and or
- - Biotin in the range of> = 20 μg to <= 800 μg, preferably in the range of> = 30 μg to <= 200 μg, preferably in the range of> = 40 μg to <= 80 μg; and or
- Steviol glycosides in the range of> = 10 mg to <= 400 mg, preferably in the range of> = 30 mg to <= 300 mg, preferably in the range of> = 80 mg to <= 200 mg.
In besonders bevorzugten Ausführungsformen umfasst die Zusammensetzung, bezogen auf eine Tagesdosis der Zusammensetzung, als wirksame Bestandteile die Stoffe:
- – 500 mg Cholin;
- – 2,2 mg Vitamin B1;
- – 2,8 mg Vitamin B2
- – 16 mg Nicotinamid;
- – 1,4 mg Vitamin B6;
- – 2,5 μg Vitamin B12;
- – 200 μg Folsäure;
- – 6 mg Pantothensäure;
- – 50 μg Biotin;
- – 2.800 mg L-(+)-Milchsäure
- - 500 mg choline;
- - 2.2 mg of vitamin B1;
- - 2.8 mg of vitamin B2
- - 16 mg nicotinamide;
- - 1.4 mg of vitamin B6;
- - 2.5 μg of vitamin B12;
- - 200 μg folic acid;
- - 6 mg pantothenic acid;
- - 50 μg biotin;
- - 2,800 mg L - (+) - lactic acid
Nachfolgendes Beispiel dient zur Veranschaulichung der vorliegenden Erfindung: Nahrungsergänzungsmittel Flüssigkonzentrat zur Zubereitung eines Getränks
Eine Portion von 3 ml Flüssigkonzentrat wird in 300–500 ml Wasser zubereitet. Pro Tag werden zwei Portionen (Tagesdosis) verzehrt. Ein Fertiggetränk kann einfach auf Basis dieses Konzentrats hergestellt werden (300 bis 500 ml auf 3 ml des zuvor beschriebenen Beispiels).A serving of 3 ml of liquid concentrate is prepared in 300-500 ml of water. Two portions (daily dose) are consumed per day. A ready-made beverage can be prepared simply on the basis of this concentrate (300 to 500 ml per 3 ml of the example described above).
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE202012003949U DE202012003949U1 (en) | 2012-04-20 | 2012-04-20 | Choline, L (+) - lactic acid and B vitamins containing composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE202012003949U DE202012003949U1 (en) | 2012-04-20 | 2012-04-20 | Choline, L (+) - lactic acid and B vitamins containing composition |
Publications (1)
Publication Number | Publication Date |
---|---|
DE202012003949U1 true DE202012003949U1 (en) | 2012-06-15 |
Family
ID=46547319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE202012003949U Expired - Lifetime DE202012003949U1 (en) | 2012-04-20 | 2012-04-20 | Choline, L (+) - lactic acid and B vitamins containing composition |
Country Status (1)
Country | Link |
---|---|
DE (1) | DE202012003949U1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015077511A1 (en) * | 2013-11-21 | 2015-05-28 | Nestec S.A. | Formulation for water-soluble vitamins to increase oral absorption and bioavailability |
WO2016185413A1 (en) * | 2015-05-20 | 2016-11-24 | Nestec S.A. | Modified release formulations |
WO2016185412A1 (en) * | 2015-05-20 | 2016-11-24 | Nestec S.A. | Immediate release formulations |
-
2012
- 2012-04-20 DE DE202012003949U patent/DE202012003949U1/en not_active Expired - Lifetime
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015077511A1 (en) * | 2013-11-21 | 2015-05-28 | Nestec S.A. | Formulation for water-soluble vitamins to increase oral absorption and bioavailability |
WO2016185413A1 (en) * | 2015-05-20 | 2016-11-24 | Nestec S.A. | Modified release formulations |
WO2016185412A1 (en) * | 2015-05-20 | 2016-11-24 | Nestec S.A. | Immediate release formulations |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69627748T2 (en) | Composition for the treatment of kidney failure | |
DE69814834T2 (en) | NUTRITIONAL COMPOSITION TO IMPROVE CELL ENERGY | |
US20070292493A1 (en) | Pharmaceutical composition and method for the transdermal delivery of calcium | |
EP2683373B1 (en) | Orthomolecular agent for countering the consequences of alcohol consumption | |
DE102007030495A1 (en) | Use of creatine containing preparation e.g. for improving memory, retentivity, long-term memory and for preventing mental fatigue condition, comprising e.g. Ginkgo biloba, ginseng and niacin | |
EP1799204A1 (en) | Composition containing omega-3 fatty acids and omega-6 fatty acids | |
DE60104853T2 (en) | Compositions comprising folic acid and zinc to improve sperm quality | |
DE202007013532U1 (en) | Composition containing phospholipids, suitable for strengthening the brain and memory function | |
AT513274B1 (en) | Dietary supplements | |
DE202012003949U1 (en) | Choline, L (+) - lactic acid and B vitamins containing composition | |
DE10326822A1 (en) | Dietary supplement, e.g. for increasing general performance, concentration and endurance, comprises NADH, L-carnitine, coenzyme Q10, L-carnosine, succinic acid, ascorbic acid and bioflavonoids | |
DE102007022694A1 (en) | Milk fat milk protein composition to improve calcium absorption | |
WO2003030914A1 (en) | Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs) | |
US20210353578A1 (en) | Dietary macro/micronutritional supplement for patients undergoing kidney dialysis | |
WO2009087988A1 (en) | Composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy | |
US11813233B2 (en) | Omega 3 fatty acids and choline as neuroprotectant in patients with no dementia | |
WO2022138866A1 (en) | Agent for improving atopic dermatitis | |
WO2013013979A1 (en) | Use of citrulline and combination compound for improving male fertility | |
WO2018039297A1 (en) | Dietary macro/micronutritional supplement for patients undergoing kidney dialysis | |
CH706776A2 (en) | Process for the improved absorption of isotonic, probiotic drinks by means of electrolysis to split the water molecule chains in microcluster formation. | |
AT412381B (en) | Combined nutritional supplement, useful particularly for increasing sporting performance, contains mixture of inorganic salts, amino acids, vitamins and carbohydrates, also creatine, inositol and tocopherol | |
DE102006030037A1 (en) | Oral product, useful for preventing and treating seborrheic dermatitis, comprises cobalamin and/or betaines | |
CA3167614C (en) | Nutritional compositions and methods containing a lignan and a methyl donor | |
DE202017006840U1 (en) | Dietary supplement comprising a galactose-containing multivitamin-mineral complex | |
DE4212122C2 (en) | Dietary low-energy food to support medical and non-medical measures against osteoporosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R207 | Utility model specification |
Effective date: 20120809 |
|
R150 | Utility model maintained after payment of first maintenance fee after three years | ||
R151 | Utility model maintained after payment of second maintenance fee after six years | ||
R079 | Amendment of ipc main class |
Free format text: PREVIOUS MAIN CLASS: A23L0001300000 Ipc: A23L0033100000 |
|
R158 | Lapse of ip right after 8 years |